Abstract:Adenosine deaminase acting on RNA 1 (ADAR1) is an RNA-editing enzyme that catalyzes adenosine-to-inosine conversions in double-stranded RNAs (dsRNAs). In mammals, ADAR1 is composed of two isoforms: a nuclear short p110 isoform and a cytoplasmic long p150 isoform. Whereas both isoforms contain right-handed dsRNA-binding and deaminase domains, ADAR1 p150 harbors a Zα domain that binds to left-handed dsRNAs, termed Z-RNAs. Myeloma differentiation-associated gene 5 (MDA5) sensing of endogenous dsRNAs as non-self leads to the induction of type I interferon (IFN)-stimulated genes, but recent studies revealed that ADAR1 p150-mediated RNA editing, but not ADAR1 p110, prevents this MDA5-mediated sensing. ADAR1 p150-specific RNA-editing sites are present and at least a Zα domain-Z-RNA interaction is required for this specificity. Mutations in the ADAR1 gene cause Aicardi-Goutières syndrome (AGS), an infant encephalopathy with type I IFN overproduction. Insertion of a point mutation in the Zα domain of the Adar1 gene induces AGS-like encephalopathy in mice, which is rescued by concurrent deletion of MDA5. This finding indicates that impaired ADAR1 p150-mediated RNA-editing is a mechanism underlying AGS caused by an ADAR1 mutation. ADAR1 p150 also prevents ZBP1 sensing of endogenous Z-RNA, which leads to programmed cell death, via the Zα domain and its RNA-editing activity. Furthermore, ADAR1 prevents protein kinase R (PKR) sensing of endogenous right-handed dsRNAs, which leads to translational shutdown and growth arrest. Thus, ADAR1 acts as a regulatory hub that blocks sensing of endogenous dsRNAs as non-self by multiple sensor proteins, both in RNA editing-dependent and -independent manners, and is a potential therapeutic target for diseases, especially cancer.

Structural impacts of two disease-linked ADAR1 mutants: a molecular dynamics study

Adenosine Deaminase Acting on RNA 1 (ADAR1) As Crucial Regulators in Cardiovascular Diseases: Structures, Pathogenesis, and Potential Therapeutic Approach

High-throughput mutagenesis reveals unique structural features of human ADAR1

Structural perspectives on adenosine to inosine RNA editing by ADARs

Impact of Disease-Associated Mutations on the Deaminase Activity of ADAR1

The role of RNA editing enzyme ADAR1 in human disease

A Structural Determinant Required for Rna Editing

Adenosine Deaminases Acting on RNA, RNA Editing, and Interferon Action

The role of dsRNA A-to-I editing catalyzed by ADAR family enzymes in the pathogeneses

Adenosine deaminases acting on RNA (ADARs): RNA-editing enzymes

Origins And Evolution Of Adar-Mediated Rna Editing

Effect of Mismatch on Binding of ADAR2/GluR-2 Pre-Mrna Complex.

Rational Design of RNA Editing Guide Strands: Cytidine Analogs at the Orphan Position

RNA editing by ADAR1 leads to context-dependent transcriptome-wide changes in RNA secondary structure

Deciphering the Biological Significance of ADAR1–Z-RNA Interactions

Origins and Evolution of ADAR‐mediated RNA Editing

Adenosine Deaminase Acting on RNA (ADAR) Enzymes: A Journey from Weird to Wondrous

Adenosine deaminase acting on RNA (ADAR1), a suppressor of double-stranded RNA–triggered innate immune responses

High-throughput virtual screening to identify potential small molecule inhibitors of the Zα domain of the adenosine deaminases acting on RNA 1(ADAR1)

The RNA-editing enzyme ADAR1: a regulatory hub that tunes multiple dsRNA-sensing pathways

Mechanisms and Implications of ADAR-mediated RNA Editing in Cancer